NCT02826512: A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

NCT02826512
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: The tumor must be BRCA1-like, as identified by Agendia’s RNA-based BRCAness classifier
Exclusions: Symptomatic brain metastases or leptomeningeal metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02826512

Comments are closed.

Up ↑